Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oyster Point Pharma, Inc. (OYST)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 |
| | 10-K | 10-K | 10-K | 10-K | 8-K | S-1/A |
| Revenues | 100.0% | | | | 100.0% | 100.0% |
| Cost of goods sold | 6.2% | | | | 121.7% | 156.5% |
| Gross profit | 93.8% | | | | -21.7% | -56.5% |
| Sales and marketing | 222.6% | | | | | |
| Research and development | 98.8% | | | | | |
| General and administrative | 166.3% | | | | 21.7% | 56.5% |
| Depreciation | 0.6% | | | | | |
| EBIT | -393.9% | | | | -121.7% | -156.5% |
| Pre-tax income | -410.2% | | | | 0.0% | -527.1% |
| Income taxes | 0.0% | | | | 0.0% | 0.0% |
| Net income | -410.2% | | | | 0.0% | -527.1% |
|